To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma A/S, a clinical-stage pharma company, today announced positive results from its Phase IIb clinical trial with pudafensine (IP2015) for the treatment of erectile dysfunction (ED). The study data analysis has demonstrated statistically significant and clinically relevant efficacy in ED-related endpoints and no observations of critical adverse events. The positive results, both regarding efficacy and safety, support further development of pudafensine aiming at registration and launch in this patient group with significant unmet medical need.
Result of incentive program LTI2023 in Initiator Pharma
The AGM held on May 26, 2023 approved two long-term incentive programs (“LTI2023”), one for Management and leading employees and one for board members.LTI2023 for Management and leading…
Initiator Pharma announces indication expansion – clinical drug candidates active in models of female sexual dysfunction
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the drug candidates, pudafensine and IP2018, have shown significant efficacy in preclinical models for Female Sexual Dysfunction (FSD). Based on the findings, the company is reviewing the potential to extend the clinical indications for the drug candidates to include FSD.
INITIATOR PHARMA: Q2 2023 REPORT
Business highlights in Q2 2023In May the Company announced that WHO had selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company’s patented…
Initiator Pharma obtains IP2018 patent in Europe for treatment of Erectile Dysfunction and Depression
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the European Patent Office (“EPO”) has granted the company’s patent application for the product candidate IP2018, targeting monoamine reuptake transporters.
Initiator Pharma announces positive results from pudafensine Phase I pharmacokinetic trial
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that it has obtained positive data from a Phase I drug formulation and pharmacokinetics study in healthy subjects evaluating optimized oral solid dosage forms of pudafensine (IP2015), enabling a smooth and efficient bridging between previous data sets into new future clinical studies for pudafensine.
Finalization of share buyback program in Initiator Pharma
Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 21 June 2023.
Initiator Pharma completes recruitment in Phase IIb trial with pudafensine (IP2015)
Initiator Pharma A/S, an emerging pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, today announced that it has completed…
Issuance of new shares, share buyback and sale of shares in connection with long term incentive program for 2022
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2022 (“LTI2022-program”) and to conduct a buyback of shares in order to sell shares to the board of directors under the LTI2022-program.